{
    "hands_on_practices": [
        {
            "introduction": "Effective patient counseling requires translating epidemiological data into individualized risk. While clinical studies often report risk in relative terms (e.g., relative risk or $RR$), patients benefit most from understanding the absolute risk. This foundational exercise practices the conversion of a given relative risk for venous thromboembolism (VTE) into an absolute incidence rate, a critical skill for communicating the safety profile of combined hormonal contraceptives. ",
            "id": "4417311",
            "problem": "A $25$-year-old non-smoking nulliparous patient initiates a combined estrogen-progestin oral contraceptive containing levonorgestrel and ethinyl estradiol (EE). Consider venous thromboembolism (VTE), defined as deep vein thrombosis and/or pulmonary embolism. Use the following foundational definitions: (i) incidence rate is the number of new events per unit of person-time, here expressed per woman-year; (ii) relative risk (RR) is the ratio of the incidence rate in the exposed group to the incidence rate in the unexposed group. Assume the VTE hazard is approximately constant over one year in women of this age, and that $RR$ is stable and applicable multiplicatively to the baseline incidence.\n\nYou are given that the baseline VTE incidence in similar women not using combined estrogen-progestin oral contraceptives (COCs) is $2$ per $10{,}000$ woman-years, and that the levonorgestrel/EE COC confers $RR=2$ relative to non-use in this population. Using these premises, determine the absolute annual VTE incidence for this patient, expressed as an incidence per $10{,}000$ woman-years. Round your final answer to four significant figures.",
            "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n- Patient characteristics: $25$-year-old non-smoking nulliparous female.\n- Exposure: Combined estrogen-progestin oral contraceptive (COC) containing levonorgestrel and ethinyl estradiol (EE).\n- Outcome: Venous thromboembolism (VTE), defined as deep vein thrombosis and/or pulmonary embolism.\n- Definition (i): Incidence rate is the number of new events per unit of person-time, expressed per woman-year.\n- Definition (ii): Relative risk ($RR$) is the ratio of the incidence rate in the exposed group to the incidence rate in the unexposed group.\n- Assumption 1: VTE hazard is approximately constant over one year in women of this age.\n- Assumption 2: $RR$ is stable and applicable multiplicatively to the baseline incidence.\n- Datum 1: Baseline VTE incidence in similar women not using COCs is $2$ per $10{,}000$ woman-years.\n- Datum 2: The levonorgestrel/EE COC confers $RR=2$ relative to non-use.\n- Objective: Determine the absolute annual VTE incidence for this patient, expressed as an incidence per $10{,}000$ woman-years.\n- Precision: Round the final answer to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated for validity.\n\n- **Scientific Grounding**: The problem is grounded in fundamental principles of epidemiology and pharmacology. The baseline incidence of VTE in young women ($2$ per $10{,}000$ woman-years) and the relative risk associated with a second-generation progestin (levonorgestrel, $RR=2$) are consistent with figures reported in major cohort and case-control studies in the medical literature. The definitions of incidence rate and relative risk are standard in epidemiology.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary data and definitions to calculate a unique, meaningful answer. The question is clear and the objective is specific.\n- **Objectivity**: The language is objective and precise, using established medical and epidemiological terminology.\n- **Consistency**: The givens are self-consistent and do not contain contradictions. The assumptions are explicitly stated and reasonable for this type of calculation.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid as it is scientifically grounded, well-posed, objective, and internally consistent. A solution will be formulated.\n\nThe objective is to calculate the absolute annual VTE incidence for the patient using the provided COC. This quantity is the incidence rate in the exposed group.\n\nLet $I_{unexp}$ denote the baseline incidence rate of VTE in the unexposed population (women not using COCs). From the problem statement, we are given:\n$$I_{unexp} = 2 \\text{ per } 10{,}000 \\text{ woman-years}$$\nLet $I_{exp}$ denote the incidence rate of VTE in the exposed population (women using the specified COC). This is the quantity we need to determine.\nLet $RR$ be the relative risk of VTE for COC users compared to non-users. The problem states:\n$$RR = 2$$\nThe problem explicitly defines relative risk as the ratio of the incidence rate in the exposed group to the incidence rate in the unexposed group. This can be written as the following equation:\n$$RR = \\frac{I_{exp}}{I_{unexp}}$$\nThe problem states that this relationship is stable and applicable multiplicatively. To find the incidence in the exposed patient, we can rearrange the equation to solve for $I_{exp}$:\n$$I_{exp} = RR \\times I_{unexp}$$\nSubstituting the given values into this equation:\n$$I_{exp} = 2 \\times (2 \\text{ per } 10{,}000 \\text{ woman-years})$$\nPerforming the multiplication:\n$$I_{exp} = 4 \\text{ per } 10{,}000 \\text{ woman-years}$$\nThe problem requires the final answer to be rounded to four significant figures. The integer $4$ can be expressed to four significant figures by including trailing zeros after the decimal point. Therefore, the absolute annual VTE incidence is $4.000$ per $10{,}000$ woman-years.",
            "answer": "$$\\boxed{4.000}$$"
        },
        {
            "introduction": "Pharmacodynamic interactions can compromise treatment efficacy, a key concern when timing the initiation of hormonal contraception after emergency use of a selective progesterone receptor modulator (SPRM) like ulipristal acetate. This problem applies core principles of first-order pharmacokinetics and competitive receptor binding to determine a clinically appropriate washout period. By calculating the time required for the SPRM concentration to fall below a threshold that minimizes antagonism, this exercise demonstrates how fundamental pharmacology directly informs evidence-based clinical guidelines. ",
            "id": "4417289",
            "problem": "A patient presents for counseling after taking a single dose of ulipristal acetate (UPA) for emergency contraception. Ulipristal acetate is a Selective Progesterone Receptor Modulator (SPRM) that exerts its effect at the progesterone receptor (PR) through competitive binding and has first-order elimination with a terminal half-life of approximately $32$ hours. The patient wishes to initiate a combined hormonal contraceptive (CHC) pill that contains a progestin, which also binds the PR as a competitive agonist. Using the law of mass action for receptor occupancy and first-order elimination kinetics, and assuming that ulipristal acetate and the CHC progestin have similar equilibrium dissociation constants at the PR so that relative receptor occupancy is proportional to ligand concentration when occupancy is not near saturation, determine the earliest CHC start time that minimizes pharmacodynamic antagonism of ulipristal acetate’s action. For clinical safety, suppose that “minimizing antagonism” corresponds to waiting until residual ulipristal acetate receptor occupancy is below $10\\%$ of its immediate post-dose value, recognizing interindividual variability and measurement uncertainty. Which of the following initiation timings best satisfies these principles while remaining clinically practical?\n\nA. Start combined hormonal contraceptives the same day as ulipristal acetate, with condom use for $7$ days\n\nB. Start combined hormonal contraceptives after $24$ hours because ulipristal acetate will be substantially reduced by then\n\nC. Start combined hormonal contraceptives at or beyond $5$ days after ulipristal acetate\n\nD. Defer combined hormonal contraceptives until the next menses to avoid any overlap\n\nE. Start combined hormonal contraceptives after $72$ hours because most of ulipristal acetate will be eliminated by then",
            "solution": "The user wants me to validate the problem statement and, if valid, derive a solution based on pharmacological principles.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Drug:** Ulipristal acetate (UPA)\n-   **Class:** Selective Progesterone Receptor Modulator (SPRM)\n-   **Mechanism:** Competitive binding at the progesterone receptor (PR).\n-   **Pharmacokinetics:** First-order elimination.\n-   **Terminal Half-life ($t_{1/2}$):** Approximately $32$ hours.\n-   **Concomitant Drug:** Combined hormonal contraceptive (CHC) containing a progestin.\n-   **Progestin Mechanism:** Competitive agonist at the PR.\n-   **Pharmacodynamic Interaction:** The CHC progestin is a competitive agonist that will antagonize the action of UPA at the PR.\n-   **Key Assumption:** UPA and the CHC progestin have similar equilibrium dissociation constants ($K_d$) at the PR. This implies that relative receptor occupancy is proportional to the ligand's concentration, particularly when receptor occupancy is not near saturation.\n-   **Objective:** Determine the earliest CHC start time that \"minimizes antagonism.\"\n-   **Quantitative Criterion:** \"Minimizing antagonism\" is defined as waiting until the residual UPA receptor occupancy falls below $10\\%$ of its immediate post-dose value.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem is grounded in established principles of pharmacokinetics (first-order elimination, half-life) and pharmacodynamics (receptor theory, competitive binding, law of mass action). The properties of ulipristal acetate (SPRM, competitive binder, half-life of $\\approx 32$ hours) and CHC progestins (PR agonists) are factually correct. The potential for pharmacodynamic antagonism between these agents is a recognized clinical issue.\n-   **Well-Posedness:** The problem provides sufficient information to arrive at a quantitative solution. It specifies the kinetic model (first-order), a key parameter ($t_{1/2} = 32$ hours), a simplifying assumption (occupancy proportional to concentration), and a clear numerical target (occupancy $< 10\\%$ of initial). A unique answer for the minimum time can be calculated.\n-   **Objectivity:** The problem is stated in precise, objective, and clinical terms. The definition of \"minimizing antagonism\" is quantified, removing ambiguity.\n\n**Step 3: Verdict and Action**\nThe problem statement is scientifically sound, well-posed, and objective. It contains no contradictions, fallacies, or fatal flaws. Therefore, the problem is **valid**, and I will proceed with the solution.\n\n### Derivation of Solution\n\nThe problem requires us to calculate the time it takes for the concentration of ulipristal acetate (UPA) to decrease to a level where its receptor occupancy is less than $10\\%$ of its initial value.\n\n$1$. **Governing Equations:**\nThe elimination of UPA is described by first-order kinetics. The concentration of the drug, $C(t)$, at time $t$ is given by:\n$$C(t) = C_0 \\left(\\frac{1}{2}\\right)^{t/t_{1/2}}$$\nwhere $C_0$ is the initial concentration at $t=0$, and $t_{1/2}$ is the elimination half-life.\n\nThe problem states that receptor occupancy, let's denote it as $\\Phi(t)$, is proportional to the ligand concentration $C(t)$. This can be written as $\\Phi(t) = k \\cdot C(t)$, where $k$ is a proportionality constant. Therefore, the ratio of receptor occupancy at time $t$ to the initial occupancy $\\Phi_0$ is equal to the ratio of the corresponding concentrations:\n$$\\frac{\\Phi(t)}{\\Phi_0} = \\frac{k \\cdot C(t)}{k \\cdot C_0} = \\frac{C(t)}{C_0}$$\n\n$2$. **Applying the Criterion:**\nThe clinical criterion is that the residual UPA receptor occupancy must be below $10\\%$ of its immediate post-dose value. Mathematically:\n$$\\frac{\\Phi(t)}{\\Phi_0}  0.10$$\nUsing the relationship derived above, this is equivalent to:\n$$\\frac{C(t)}{C_0}  0.10$$\n\n$3$. **Solving for Time ($t$):**\nWe substitute the first-order kinetics equation into our inequality:\n$$\\left(\\frac{1}{2}\\right)^{t/t_{1/2}}  0.10$$\nWe are given $t_{1/2} \\approx 32$ hours.\n$$\\left(\\frac{1}{2}\\right)^{t/32}  0.10$$\nTo solve for $t$, we take the natural logarithm ($\\ln$) of both sides. Since $\\ln(x)$ is an increasing function, the direction of the inequality is preserved.\n$$\\ln\\left[\\left(\\frac{1}{2}\\right)^{t/32}\\right]  \\ln(0.10)$$\nUsing the logarithm property $\\ln(a^b) = b \\cdot \\ln(a)$:\n$$\\frac{t}{32} \\ln\\left(\\frac{1}{2}\\right)  \\ln(0.10)$$\nSince $\\ln(1/2) = -\\ln(2)$ and $\\ln(0.10) = -\\ln(10)$:\n$$-\\frac{t}{32} \\ln(2)  -\\ln(10)$$\nMultiplying both sides by $-1$ reverses the inequality's direction:\n$$\\frac{t}{32} \\ln(2) > \\ln(10)$$\nNow, we isolate $t$:\n$$t > 32 \\cdot \\frac{\\ln(10)}{\\ln(2)}$$\nThe term $\\frac{\\ln(10)}{\\ln(2)}$ represents the number of half-lives required for the concentration to fall to $1/10$ of its initial value.\nUsing the values $\\ln(10) \\approx 2.3026$ and $\\ln(2) \\approx 0.6931$:\n$$t > 32 \\cdot \\frac{2.3026}{0.6931} \\approx 32 \\cdot 3.3219 \\text{ hours}$$\n$$t > 106.3 \\text{ hours}$$\n\n$4$. **Interpreting the Result:**\nThe calculation shows that one must wait longer than $106.3$ hours for the UPA receptor occupancy to drop below the $10\\%$ threshold. To convert this to days:\n$$t_{\\text{days}} = \\frac{106.3 \\text{ hours}}{24 \\text{ hours/day}} \\approx 4.43 \\text{ days}$$\nTherefore, to meet the criterion, the CHC should be initiated at a time $t > 4.43$ days. Given the instruction to consider \"interindividual variability and measurement uncertainty,\" a clinically practical approach would be to round this up to the next whole day, suggesting a start time of $5$ days or later.\n\n### Option-by-Option Analysis\n\n**A. Start combined hormonal contraceptives the same day as ulipristal acetate, with condom use for $7$ days**\nAt $t \\approx 0$, the UPA concentration and its receptor occupancy are at their peak ($\\approx 100\\%$ of the initial value). Starting a competitive agonist (the CHC progestin) at this time would create maximum pharmacodynamic antagonism, directly contradicting the goal of minimizing it. **Incorrect**.\n\n**B. Start combined hormonal contraceptives after $24$ hours because ulipristal acetate will be substantially reduced by then**\nAt $t=24$ hours, the fraction of UPA remaining is $(\\frac{1}{2})^{24/32} = (\\frac{1}{2})^{0.75} \\approx 0.595$. This corresponds to $\\approx 59.5\\%$ of the initial receptor occupancy, which is substantially higher than the specified $10\\%$ threshold. **Incorrect**.\n\n**C. Start combined hormonal contraceptives at or beyond $5$ days after ulipristal acetate**\n$5$ days is equivalent to $5 \\times 24 = 120$ hours. This time ($120$ hours) is greater than our calculated minimum of $106.3$ hours. Let's calculate the occupancy at $120$ hours:\nFraction remaining = $(\\frac{1}{2})^{120/32} = (\\frac{1}{2})^{3.75} \\approx 0.074$.\nThis corresponds to $\\approx 7.4\\%$ of the initial occupancy, which is safely below the $10\\%$ threshold. This timing satisfies the quantitative criterion, accounts for variability by providing a safety margin beyond the calculated $4.43$ days, and represents the earliest practical option that does so. **Correct**.\n\n**D. Defer combined hormonal contraceptives until the next menses to avoid any overlap**\nWhile waiting for the next menses would ensure that UPA is completely eliminated and thus avoid any antagonism, the problem asks for the *earliest* start time that meets the criteria. Deferring for several weeks is significantly longer than the calculated minimum of $\\approx 4.43$ days. Therefore, this option is not the *best* answer as it is unnecessarily delayed. **Incorrect**.\n\n**E. Start combined hormonal contraceptives after $72$ hours because most of ulipristal acetate will be eliminated by then**\n$72$ hours is $3$ days. At $t=72$ hours, the fraction of UPA remaining is $(\\frac{1}{2})^{72/32} = (\\frac{1}{2})^{2.25} \\approx 0.21$. This corresponds to $\\approx 21\\%$ of the initial receptor occupancy, which is more than double the required $10\\%$ threshold. The statement that \"most\" will be eliminated is vague and, in this context, insufficient. **Incorrect**.",
            "answer": "$$\\boxed{C}$$"
        },
        {
            "introduction": "The clinical guidelines for managing missed contraceptive pills are based on complex pharmacodynamic principles governing the suppression and recovery of the hypothalamic-pituitary-ovarian (HPO) axis. This advanced problem moves beyond simple rules to a quantitative model, using differential equations to describe the decay and restoration of HPO axis suppression. By calculating and comparing the cumulative risk of ovulation in different missed-pill scenarios, you will gain a deeper, mechanistic understanding of why the timing of missed pills is so critical to maintaining contraceptive efficacy. ",
            "id": "4417295",
            "problem": "A combined oral contraceptive (COC) user taking a standard $28$-day regimen with $21$ active pills followed by $7$ placebo pills maintains suppression of the Hypothalamic-Pituitary-Ovarian (HPO) axis at a steady-state suppression index $S_{\\mathrm{ss}}$ during perfect adherence. In a pharmacodynamic model consistent with first-order processes, when active pills are not taken, the suppression index $S(t)$ decays exponentially according to $\\frac{dS}{dt}=-k_{\\mathrm{off}} S$ with $k_{\\mathrm{off}}=\\ln(2)/t_{1/2,\\mathrm{off}}$, and when active pills are resumed, $S(t)$ recovers toward $S_{\\mathrm{ss}}$ as $\\frac{dS}{dt}=\\frac{S_{\\mathrm{ss}}-S}{\\tau_{\\mathrm{on}}}$. Ovulatory drive is considered negligible when $S(t)\\ge S_c$ and proportional to the suppression deficit when $S(t)S_c$, quantified by $g(t)=\\max\\{0,1-S(t)/S_c\\}$. The cumulative ovulatory activation over an interval $[0,T]$ is $A=\\int_{0}^{T} g(t)\\,dt$. In the rare-event approximation for Poisson processes, the ovulation probability $R$ over $[0,T]$ satisfies $R\\approx \\lambda A$ for a constant $\\lambda$, so that the relative risk between two scenarios equals the ratio of their $A$ values.\n\nAssume the following parameters: $S_{\\mathrm{ss}}=1$ (dimensionless), threshold $S_c=0.5$ (dimensionless), off-suppression half-life $t_{1/2,\\mathrm{off}}=1.5$ days, and on-suppression time constant $\\tau_{\\mathrm{on}}=1$ day. Consider two scenarios of missing $3$ consecutive active pills:\n\n- Week $2$ miss: the user is adherent through week $1$, then misses pills on cycle days $8$–$10$ (a continuous $3$-day hormone-free interval), resumes active pills on day $11$ and continues through day $21$, then takes placebo on days $22$–$28$. Define the cumulative activation $A_{\\mathrm{W2}}$ as the time integral of $g(t)$ from the start of the first missed pill until the earliest time when $S(t)$ again reaches at least $S_c$ after resuming active pills.\n- Week $3$ miss: the user is adherent through day $18$, then misses pills on days $19$–$21$ and proceeds directly to the standard $7$-day placebo (totaling a continuous $10$-day hormone-free interval). Define the cumulative activation $A_{\\mathrm{W3}}$ as the time integral of $g(t)$ from the start of the first missed pill until the end of placebo (a total of $10$ days off hormones).\n\nUsing the model and parameters above, compute the ovulation risk change defined as the dimensionless ratio $\\mathrm{RR}=A_{\\mathrm{W2}}/A_{\\mathrm{W3}}$. Express your final answer as a dimensionless ratio and round to four significant figures.",
            "solution": "The problem statement has been validated and is found to be scientifically grounded, well-posed, and objective. It presents a simplified but coherent pharmacodynamic model for which all necessary parameters and conditions are provided to compute a unique, meaningful solution.\n\nThe problem requires the calculation of a dimensionless ratio $\\mathrm{RR}=A_{\\mathrm{W2}}/A_{\\mathrm{W3}}$, where $A_{\\mathrm{W2}}$ and $A_{\\mathrm{W3}}$ are cumulative ovulatory activation metrics for two different scenarios of missing combined oral contraceptive pills.\n\nFirst, we establish the model parameters and constants.\nThe given parameters are:\n- Steady-state suppression index: $S_{\\mathrm{ss}}=1$\n- Critical suppression threshold: $S_c=0.5$\n- Off-suppression half-life: $t_{1/2,\\mathrm{off}}=1.5$ days\n- On-suppression time constant: $\\tau_{\\mathrm{on}}=1$ day\n\nThe decay rate constant $k_{\\mathrm{off}}$ is given by:\n$$k_{\\mathrm{off}} = \\frac{\\ln(2)}{t_{1/2,\\mathrm{off}}} = \\frac{\\ln(2)}{1.5} \\, \\text{day}^{-1}$$\n\nThe ovulatory drive function is $g(t)=\\max\\{0,1-S(t)/S_c\\}$, and the cumulative activation is $A = \\int g(t) dt$. Activation occurs only when $S(t)  S_c$. Let $t=0$ be the time the first pill is missed in each scenario. The initial condition is perfect adherence, so $S(0) = S_{\\mathrm{ss}} = 1$.\n\nWe first find the time $t_c$ at which the suppression index $S(t)$ decays to the critical value $S_c$. During the hormone-free interval, the suppression index decays according to the solution of $\\frac{dS}{dt}=-k_{\\mathrm{off}} S$, which is $S(t) = S(0) \\exp(-k_{\\mathrm{off}} t)$.\n$S(t_c) = S_c \\implies S_{\\mathrm{ss}} \\exp(-k_{\\mathrm{off}} t_c) = S_c$\n$1 \\cdot \\exp(-k_{\\mathrm{off}} t_c) = 0.5$\n$-k_{\\mathrm{off}} t_c = \\ln(0.5) = -\\ln(2)$\n$t_c = \\frac{\\ln(2)}{k_{\\mathrm{off}}} = \\frac{\\ln(2)}{\\ln(2)/1.5} = 1.5 \\, \\text{days}$\n\nNow, we calculate the cumulative activation for each scenario.\n\n**Scenario 2: Week 3 Miss ($A_{\\mathrm{W3}}$)**\nIn this scenario, there is a continuous $10$-day hormone-free interval. The suppression index decays for the entire duration, $t \\in [0, 10]$. Activation occurs for $t \\in [t_c, 10]$.\n$$A_{\\mathrm{W3}} = \\int_{0}^{10} g(t) \\, dt = \\int_{t_c}^{10} \\left(1 - \\frac{S(t)}{S_c}\\right) dt$$\nWith $S(t) = \\exp(-k_{\\mathrm{off}}t)$, $S_c = 0.5$, and $t_c=1.5$:\n$$A_{\\mathrm{W3}} = \\int_{1.5}^{10} \\left(1 - \\frac{\\exp(-k_{\\mathrm{off}}t)}{0.5}\\right) dt = \\int_{1.5}^{10} \\left(1 - 2\\exp(-k_{\\mathrm{off}}t)\\right) dt$$\n$$A_{\\mathrm{W3}} = \\left[ t - 2\\left(\\frac{\\exp(-k_{\\mathrm{off}}t)}{-k_{\\mathrm{off}}}\\right) \\right]_{1.5}^{10} = \\left[ t + \\frac{2}{k_{\\mathrm{off}}}\\exp(-k_{\\mathrm{off}}t) \\right]_{1.5}^{10}$$\n$$A_{\\mathrm{W3}} = \\left(10 + \\frac{2}{k_{\\mathrm{off}}}\\exp(-10k_{\\mathrm{off}})\\right) - \\left(1.5 + \\frac{2}{k_{\\mathrm{off}}}\\exp(-1.5k_{\\mathrm{off}})\\right)$$\nWe know $1.5k_{\\mathrm{off}} = \\ln(2)$, so $\\exp(-1.5k_{\\mathrm{off}}) = \\exp(-\\ln(2)) = 0.5$.\nAlso, $10k_{\\mathrm{off}} = 10 \\frac{\\ln(2)}{1.5} = \\frac{20}{3}\\ln(2)$, so $\\exp(-10k_{\\mathrm{off}}) = \\exp(-\\frac{20}{3}\\ln(2)) = 2^{-20/3}$.\n$$A_{\\mathrm{W3}} = 8.5 + \\frac{2}{k_{\\mathrm{off}}}(\\exp(-10k_{\\mathrm{off}}) - 0.5)$$\nSubstituting $k_{\\mathrm{off}} = \\frac{\\ln(2)}{1.5}$:\n$$A_{\\mathrm{W3}} = 8.5 + \\frac{2 \\cdot 1.5}{\\ln(2)}(2^{-20/3} - 0.5) = 8.5 + \\frac{3}{\\ln(2)}(2^{-20/3} - 0.5)$$\nNumerically:\n$A_{\\mathrm{W3}} \\approx 8.5 + \\frac{3}{0.693147}(0.009921 - 0.5) \\approx 8.5 + 4.328085(-0.490079) \\approx 8.5 - 2.121356 = 6.378644$\n\n**Scenario 1: Week 2 Miss ($A_{\\mathrm{W2}}$)**\nThis scenario involves two phases: a $3$-day decay period followed by a recovery period.\n**Phase 1: Decay ($t \\in [0, 3]$)**\nActivation occurs for $t \\in [t_c, 3] = [1.5, 3]$. The cumulative activation during this phase, $A_{\\mathrm{decay}}$, is:\n$$A_{\\mathrm{decay}} = \\int_{1.5}^{3} \\left(1 - 2\\exp(-k_{\\mathrm{off}}t)\\right) dt = \\left[ t + \\frac{2}{k_{\\mathrm{off}}}\\exp(-k_{\\mathrm{off}}t) \\right]_{1.5}^{3}$$\n$$A_{\\mathrm{decay}} = \\left(3 + \\frac{2}{k_{\\mathrm{off}}}\\exp(-3k_{\\mathrm{off}})\\right) - \\left(1.5 + \\frac{2}{k_{\\mathrm{off}}}\\exp(-1.5k_{\\mathrm{off}})\\right)$$\nWe have $3k_{\\mathrm{off}} = 3 \\frac{\\ln(2)}{1.5} = 2\\ln(2) = \\ln(4)$, so $\\exp(-3k_{\\mathrm{off}}) = \\exp(-\\ln(4)) = 0.25$.\n$$A_{\\mathrm{decay}} = 1.5 + \\frac{2}{k_{\\mathrm{off}}}(0.25 - 0.5) = 1.5 - \\frac{0.5}{k_{\\mathrm{off}}} = 1.5 - \\frac{0.5 \\cdot 1.5}{\\ln(2)} = 1.5 - \\frac{0.75}{\\ln(2)}$$\nThe suppression index at the end of this phase is $S(3) = \\exp(-3k_{\\mathrm{off}}) = 0.25$. This is the initial condition for the recovery phase.\n\n**Phase 2: Recovery ($t \\ge 3$)**\nLet's define a new time variable $t' = t - 3$. The recovery starts at $t'=0$. The governing equation is $\\frac{dS}{dt'}=\\frac{S_{\\mathrm{ss}}-S}{\\tau_{\\mathrm{on}}}$. With $S_{\\mathrm{ss}}=1$ and $\\tau_{\\mathrm{on}}=1$, this is $\\frac{dS}{dt'} = 1-S$. The solution is of the form $S(t') = 1 - C\\exp(-t')$.\nUsing the initial condition $S(0) = 0.25$:\n$0.25 = 1 - C\\exp(0) \\implies C = 0.75$.\nSo, $S(t') = 1 - 0.75\\exp(-t')$.\nActivation occurs as long as $S(t')  S_c=0.5$. We find the time $t'_c$ when recovery to the threshold occurs:\n$$0.5 = 1 - 0.75\\exp(-t'_c) \\implies 0.75\\exp(-t'_c) = 0.5 \\implies \\exp(-t'_c) = \\frac{0.5}{0.75} = \\frac{2}{3}$$\n$$t'_c = -\\ln(2/3) = \\ln(3/2)$$\nThe cumulative activation during recovery, $A_{\\mathrm{recov}}$, is integrated from $t'=0$ to $t'_c$:\n$$A_{\\mathrm{recov}} = \\int_{0}^{t'_c} \\left(1 - \\frac{S(t')}{S_c}\\right) dt' = \\int_{0}^{\\ln(3/2)} \\left(1 - \\frac{1 - 0.75\\exp(-t')}{0.5}\\right) dt'$$\n$$A_{\\mathrm{recov}} = \\int_{0}^{\\ln(3/2)} \\left(1 - (2 - 1.5\\exp(-t'))\\right) dt' = \\int_{0}^{\\ln(3/2)} \\left(-1 + 1.5\\exp(-t')\\right) dt'$$\n$$A_{\\mathrm{recov}} = \\left[-t' - 1.5\\exp(-t')\\right]_{0}^{\\ln(3/2)}$$\n$$A_{\\mathrm{recov}} = \\left(-\\ln(3/2) - 1.5\\exp(-\\ln(3/2))\\right) - \\left(-0 - 1.5\\exp(0)\\right)$$\n$$A_{\\mathrm{recov}} = \\left(-\\ln(3/2) - 1.5\\left(\\frac{2}{3}\\right)\\right) - (-1.5) = -\\ln(3/2) - 1 + 1.5 = 0.5 - \\ln(1.5)$$\nThe total cumulative activation for Scenario 1 is the sum of the activations from both phases:\n$$A_{\\mathrm{W2}} = A_{\\mathrm{decay}} + A_{\\mathrm{recov}} = \\left(1.5 - \\frac{0.75}{\\ln(2)}\\right) + (0.5 - \\ln(1.5))$$\n$$A_{\\mathrm{W2}} = 2 - \\frac{0.75}{\\ln(2)} - \\ln(1.5)$$\nNumerically:\n$A_{\\mathrm{W2}} \\approx 2 - \\frac{0.75}{0.693147} - 0.405465 \\approx 2 - 1.082021 - 0.405465 = 0.512514$\n\n**Relative Risk Calculation**\nFinally, we compute the ratio $\\mathrm{RR}=A_{\\mathrm{W2}}/A_{\\mathrm{W3}}$:\n$$\\mathrm{RR} = \\frac{A_{\\mathrm{W2}}}{A_{\\mathrm{W3}}} = \\frac{0.512514}{6.378644} \\approx 0.0803483$$\nRounding to four significant figures, we get $0.08035$.",
            "answer": "$$\\boxed{0.08035}$$"
        }
    ]
}